Overview
To evaluate the effectiveness, feasibility, acceptability, and appropriateness of an ototoxicity screening protocol among head and neck (H&N) cancer patients followed in survivorship clinic that received cisplatin-based chemoradiation therapy (CRT).
Eligibility
Inclusion Criteria:
- Adult (≥ 18 years old)
- H&N cancer patients will be eligible for inclusion if they have previously undergone cisplatin-based CRT or radiotherapy, including proton therapy, intensity-modulated radiation therapy, and adaptive radiotherapy-surgery with curative intent (i.e., definitive, neoadjuvant, or adjuvant) or definitive surgery with neoadjuvant or adjuvant radiation.
Exclusion Criteria:
- Patient has been evaluated by an audiologist within the past 12 months
- Use of a hearing aid
- Received a cochlear implant
- Cannot complete simple forms in English